Serenex Inc., 323 Foster Street, Durham, NC 27701, USA.
Bioorg Med Chem Lett. 2012 Apr 1;22(7):2550-4. doi: 10.1016/j.bmcl.2012.01.137. Epub 2012 Feb 15.
A novel class of Hsp90 inhibitors, structurally distinct from previously reported scaffolds, was developed from rational design and optimization of a compound library screen hit. These aminoquinazoline derivatives, represented by compound 15 (SNX-6833) or 1-(2-amino-4-methylquinazolin-7-yl)-3,6,6-trimethyl-6,7-dihydro-1H-indol-4(5H)-one, selectively bind to Hsp90 and inhibit its cellular activities at concentrations as low as single digit nanomolar.
开发了一类新型的 Hsp90 抑制剂,其结构与以前报道的支架明显不同,是从化合物库筛选命中的合理设计和优化而来。这些氨基喹唑啉衍生物以化合物 15(SNX-6833)或 1-(2-氨基-4-甲基喹唑啉-7-基)-3,6,6-三甲基-6,7-二氢-1H-吲哚-4(5H)-酮为代表,以低至个位数纳摩尔的浓度选择性结合 Hsp90 并抑制其细胞活性。